Intervacc AB (publ) (IVACC.ST) Research

Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.

Market snapshot

Symbol
IVACC.ST
Price
$1.30
Day change
-0.76%
Market cap
$443.1M
P/E ratio
-5.04x
52-week range
0.572-1.462
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Acarix AB (publ) (ACARIX.ST)
  • Ascelia Pharma AB (publ) (ACE.ST)
  • Elicera Therapeutics AB (publ) (ELIC.ST)
  • Mendus AB (publ) (IMMU.ST)
  • IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
  • Isofol Medical AB (publ) (ISOFOL.ST)
  • Karolinska Development AB (publ) (KDEV.ST)
  • Magle Chemoswed Holding AB (publ) (MAGLE.ST)

Open Intervacc AB (publ) (IVACC.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.